We are live on ! Find out more

Absci

ABSI

Market cap $1.52B

8.88 USD

+0.14

1.6%

At close Updated Oct 15, 4:00 PM EDT

Pre-market

After hours

8.89

+0.01

0.11%

1 day

1.6%

5 days

-3.48%

1 month

11.84%

3 months

-9.02%

6 months

180.13%

Year to date

145.98%

1 year

77.6%

5 years

-16.46%

10 years

-58.87%

About: Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.

Employees: 140

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 27.3%

Neutral 54.5%

Negative 18.2%

Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026

VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2026 before market open on Thursday, November 12, 2026.

Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026

Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept.

Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade)

Absci Corporation is upgraded to “Buy” following positive interim Phase 1 data for ABS-201 in androgenetic alopecia [AGA]. ABS-201 demonstrated an excellent PK profile, enabling infrequent dosing [2–3 injections per 6 months] and strong safety/tolerability in SAD cohorts. Upcoming catalysts include 13-week interim proof-of-concept data in 2H 2026 and 26-week topline results in early 2027 for ABS-201 in AGA.

Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade)

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Sept.

Absci to Participate in Upcoming Investor Conferences

24/7 Wall Street

AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next

On August 14, 2026, Advanced Micro Devices (NASDAQ:AMD | AMD Price Prediction) filed its first-ever 13F, pulling back the curtain on a $1.31 billion equity portfolio concentrated in just six positions.

AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next

Zacks Investment Research

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript

Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript

Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript

Absci Q2 Earnings Call Highlights

Absci NASDAQ: ABSI outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis, while reporting a larger cash balance following a June equity offering and strategic investment from Eli Lilly.

Absci Q2 Earnings Call Highlights

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half of 2028 VANCOUVER, Wash. and NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended June 30, 2026.

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

See News Rankings

Price charts implemented using Lightweight Charts™